Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NervGen Pharma Corp. (V:NGEN)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for NGEN within the last 6 months
Loading...
See all filings within the past 6 months

Company News

May 20, 2020 16:13 ET
NervGen Pharma Corp. Closes Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce that it has closed a non-brokered private placement of 1,806,827 units of the Company at a price of CAD$1.25 per unit, for aggregate gross proceeds to the Company of CAD$2,258,534.
Read full article
Apr 29, 2020 17:47 ET
NervGen Pharma Reports 2019 Year End Results
Phase 1 Clinical Study Remains on Track for Q4 2020
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
9.76
8.56
Price to Book - most recent quarter
9.04
4.01
2.33
Price to Cash Flow per share - TTM
--
30.43
8.83
Price to Free Cash Flow per share - TTM
--
38.56
14.58
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
May 15, 202018,4345,052
Apr 30, 202013,3828,307
Apr 15, 20205,0753,006
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

NervGen Pharma Corp. is a Canada-based biotechnology company. The Company is focused on developing solutions for the treatment of nerve damage and neurodegenerative diseases. The Company is also developing drugs for the treatment of spinal cord injury (SCI), multiple sclerosis (MS) and Alzheimer's disease. Its platform technology targets protein tyrosine phosphatase sigma (PTP sigma), a neural receptor that impedes nerve repair. The PTP sigma receptor promote regeneration of damaged nerves, increase plasticity and stimulate remyelination in animal models. The Company's lead product is NVG-291 referred to intracellular signaling peptide (ISP), treatment for SCI and MS.

See business summary

 

Twitter

Search (past week) for $NGEN.CA NGEN.V